Search Results - "Rekowski, J."

YjbH contributes to staphylococcus aureus skin pathology and immune response through Agr-mediated α-toxin regulation by McReynolds, Aubrey K G, Pagella, Emma A, Ridder, Miranda J, Rippee, Olivia, Clark, Zachary, Rekowski, Michaella J, Pritchard, Michele T, Bose, Jeffrey L

“…is the most common cause of skin and soft tissue infections (SSTIs) with Methicillin-Resistant (MRSA) strains being a major contributor in both community and…”
Get full text

Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023 by Villacampa, G., Dennett, S., Mello, E., Holton, J., Lai, X., Kilburn, L., Bliss, J., Rekowski, J., Yap, C.

“…In a competitive landscape with many ongoing adjuvant randomised controlled trials (RCTs), the prevalence of trials that failed to recruit their targeted…”
Get full text

Engineering of pyranose 2-oxidase from Peniophora gigantea towards improved thermostability and catalytic efficiency by BASTIAN, Sabine, REKOWSKI, Matthias J, WITTE, Klaus, HECKMANN-POHL, Dorothée M, GIFFHORN, Friedrich

“…To improve the stability and catalytic efficiency of pyranose 2-oxidase (P2Ox) by molecular enzyme evolution, we cloned P2Ox cDNA by RACE-PCR from a cDNA…”
Get full text

1840P RNASEH2B loss and PARP inhibition (parpi) in metastatic castration resistant prostate cancer (mCRPC) by Carmichael, J., Figueiredo, I., Gurel, B., Yuan, W., Rekowski, J., Seed, G., Carreira, S., Bertan, C., Beije, N., Westaby, D., Guo, C., Neeb, A., Welti, J., Gallagher, L., Bogdan, D., Crespo, M., Riiisneas, R., Lord, C., Sharp, A., de Bono, J.S.

Get full text

121P ATM germline mutations in lethal prostate cancer by Grochot, R.M., Carreira, S., Miranda, S., Figueiredo, I., Bertan, C., Rekowski, J., Yuan, W., Ferreira, A., Riisnaes, R., Neeb, A., Gurel, B., Fenor de la Maza, M.D.L.D., Carmichael, J., Westaby, D., Guo, C., Sharp, A., de Bono, J.S.

Get full text

687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours by de Bono, J.S., Lord, S., Yap, C., Miranda, S., Veal, G.J., Chandran, K., Paschalis, A., Peron, C., Rekowski, J., Gurel, B., Paisley, D., McGuigan, L., Ingram, P.J., Kwek, K.Y., Halbert, G., Westwood, N.B., Griffin, A.E., Kostaras, L., Boyd-Kirkup, J.D., Walter, H.S.

Get full text

1839P Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers by Seed, G., Greening, S., Goodall, J., Rekowski, J., Christova, R., Mehra, N., Eisenberger, M., Fizazi, K., Tombal, B., Wülfing, C., Sternberg, C.N., Castellano Gauna, D.E., Oudard, S., Sartor, O., Geffriaud-Ricouard, C., Chadjaa, M., Mace, S., Carreira, S., Yuan, W., de Bono, J.S.

Get full text

Safety of Simultaneous Coronary Artery Bypass Grafting and Carotid Endarterectomy Versus Isolated Coronary Artery Bypass Grafting: A Randomized Clinical Trial by Weimar, C., Bilbilis, K., Rekowski, J., Holst, T., Beyersdorf, F., Breuer, M.

Get full text

454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) by Guo, C., Sharp, A., Vogl, U., Colombo, I., Stathis, A., Jain, S., Chandran, K., Tiu, C., Paschalis, A., Matthews, R.E., Figueiredo, I., Rekowski, J., Yap, C., de los Dolores Fenor de la Maza, M., Turner, A., Badham, H.C., Parmar, M., Raynaud, F., Alimonti, A., de Bono, J.S.

Get full text

77P Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer by Jiménez-Vacas, J.M., Westaby, D., Figueiredo, I., De Haven Brandon, A., Padilha, A., Yuan, W., Gurel, B., Miranda, S., Coleman, I., Neeb, A., Rekowski, J., Wilkinson, S., Chau, C., Figg, W.D., Sowalsky, A.G., Nelson, P., Carreira, S., Balk, S.P., de Bono, J.S., Sharp, A.

Get full text

79MO Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: The DEFINE (DosE FIndiNg Extensions) study by Solovyeva, O., Dimairo, M., Weir, C., de Bono, J.S., Bedding, A., Chan, A-W., Espinasse, A., Evans, T.R.J., Hee, S.W., Hopewell, S., Hughes, S., Jaki, T., Kightley, A., Lee, S., Mander, A., Patel, D., Rantell, K., Rekowski, J., Ursino, M., Yap, C.

Get full text

Proteomic profiling of bronchoalveolar lavage fluid uncovers protein clusters linked to survival in idiopathic forms of interstitial lung disease by Ngo, Linh T., Rekowski, Michaella J., Koestler, Devin C., Yorozuya, Takafumi, Saito, Atsushi, Azeem, Imaan, Harrison, Alexis, Demoruelle, M. Kristen, Boomer, Jonathan, England, Bryant R., Wolters, Paul, Molyneaux, Philip L., Castro, Mario, Lee, Joyce S., Solomon, Joshua J., Koronuma, Koji, Washburn, Michael P., Matson, Scott M.

“…Background Idiopathic interstitial pneumonias (IIPs) such as idiopathic pulmonary fibrosis (IPF) and interstitial pneumonia with autoimmune features (IPAF),…”
Get full text